The very obvious claim would be that there's still a shortage of supply in EU.
Ok, but that’s essentially the opposite argument to the one made by jq in the bottom of #msg-75115136.
Your second point—that Vpriv's orphan exclusivity is not relevant to PLX because the two drugs are not considered to have the same active ingredient—seems like the stronger of the two arguments, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.